Pan-coronavirus fusion inhibitors to combat COVID-۱۹
- سال انتشار: 1401
- محل انتشار: چهارمین کنگره پژوهشی دانشجویان دانشگاه علوم پزشکی هرمزگان
- کد COI اختصاصی: HUMS04_171
- زبان مقاله: انگلیسی
- تعداد مشاهده: 214
نویسندگان
Zahra jadali Student research committee, Larestan University of Medical Sciences, Larestan, Iran
Zohreh Nasrollahzadeh Mashhad University of Medical Sciences Health education
Reza Aghahusseini Dalir ShahidBeheshti university of medical sciences
Sanli Bagheri Babakandi Student Research Committee, Alborz University of Medical Sciences, Alborz, Iran
Mohammad Ghadirian Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
Bachelor student of radiology Faculty of Para medicine, Department of medicine, Bushehr University of Medical Science, Bushehr, Iran
چکیده
Introduction and objective: There is presently an international pandemic prompted with the aid of using Coronavirus sickness ۲۰۱۹ (COVID-۱۹), a contamination because of excessive acute breathing syndrome Coronavirus ۲ (SARS-CoV-۲). A surprisingly powerful countermeasure to present day and destiny outbreaks of infectious illnesses because of rising and reemerging Coronaviruses may be executed with the aid of using growing surprisingly powerful pan-CoV inhibitor-primarily based totally prophylactics and therapeutics.Method: In the forthcoming systematic study, the required data were collected using keywords and citing valid databases such as: Scopus PubMed, Google Scholar and ProQuest. The statistical population of the study includes all studies conducted up to ۲۰۲۲ in the field of Pan-coronavirus fusion inhibitors to combat COVID-۱۹. After reviewing the relevant Results and evaluating the data quality, a total of ۲۰articles were analyzedResult: Since the spike (S) protein of HcoVs (Human Coronaviruses) is chargeable for the virus' attachment to and access into a bunch cellular, figuring out a powerful pan-CoV inhibitor-primarily based totally drug is essential. A subunit vaccine primarily based totally on the S protein receptor-binding area (RBD) turned into proposed for the primary time. SARS-CoV-۲'s S protein, however, is a lot higher at mediating cellular-to-cellular fusion. SARS-CoV-۲-۲ and anti-S۱ area antibodies have negative cross-reactivity. CoVsV input cells with the aid of using binding to the cell receptors and priming their S proteins with host cellular proteases. Antibodies and vaccines goal the S protein due to the fact it's far exposed at the floor of the mature virus particle. SARS-CoV-۲ may be averted and handled with a robust antibody concentrated on the RBD in S protein. Coronavirus S protein's RBD is surprisingly mutable. In order to layout peptide-primarily based totally viral fusion inhibitors, lipid conjugation has been verified to be a beneficial device for enhancing antiviral activity because it gives a platform for conjugating lipids.Conclusion: RBDsDs might not be perfect goals for novel pan-CoV inhibitors. There isn't any doubt that many get away mutations are focused on HCoV RBD. A coronavirus with mutations in RBD is anticipated to be handled with an aggregate of RBD-particular antibodies and pan-CoV fusion inhibitors.کلیدواژه ها
heat-treatment، SARS-CoV-۲، SARS-CoV-۲ viability، SARS detection، fusion inhibitمقالات مرتبط جدید
- Artificial intelligence-based Diagnostic Approaches for Alzheimer's Disease Using Medical Imaging
- Artificial Intelligence-Based Telehealth Care in maternal health
- سیستم های هوش مصنوعی در پیشگیری و ارتقای سلامت عمومی
- Efficient Multi-Label Retinal Disease Classification with CLIP, LoRA, and Shadow Loss on the OIA-ODIR Dataset
- هوش مصنوعی در ژنتیک
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.